Bruce L Levine
Bruce L Levine
Barbara and Edward Netter Professor in Cancer Gene Therapy, Department of Pathology and Laboratory
Potvrđena adresa e-pošte na
Chimeric antigen receptor T cells for sustained remissions in leukemia
SL Maude, N Frey, PA Shaw, R Aplenc, DM Barrett, NJ Bunin, A Chew, ...
New England Journal of Medicine 371 (16), 1507-1517, 2014
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, ...
New England Journal of Medicine 378 (5), 439-448, 2018
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
DL Porter, BL Levine, M Kalos, A Bagg, CH June
New England Journal of Medicine 365 (8), 725-733, 2011
Chimeric antigen receptor–modified T cells for acute lymphoid leukemia
SA Grupp, M Kalos, D Barrett, R Aplenc, DL Porter, SR Rheingold, ...
New England Journal of Medicine 368 (16), 1509-1518, 2013
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
M Kalos, BL Levine, DL Porter, S Katz, SA Grupp, A Bagg, CH June
Science translational medicine 3 (95), 95ra73-95ra73, 2011
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
DL Porter, WT Hwang, NV Frey, SF Lacey, PA Shaw, AW Loren, A Bagg, ...
Science translational medicine 7 (303), 303ra139-303ra139, 2015
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV
P Tebas, D Stein, WW Tang, I Frank, SQ Wang, G Lee, SK Spratt, ...
New England Journal of Medicine 370 (10), 901-910, 2014
Chimeric antigen receptor T cells in refractory B-cell lymphomas
SJ Schuster, J Svoboda, EA Chong, SD Nasta, AR Mato, Ö Anak, ...
New England Journal of Medicine 377 (26), 2545-2554, 2017
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
DM O’Rourke, MLP Nasrallah, A Desai, JJ Melenhorst, K Mansfield, ...
Science translational medicine 9 (399), eaaa0984, 2017
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
JA Fraietta, SF Lacey, EJ Orlando, I Pruteanu-Malinici, M Gohil, S Lundh, ...
Nature medicine 24 (5), 563-571, 2018
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics
CG Brunstein, JS Miller, Q Cao, DH McKenna, KL Hippen, J Curtsinger, ...
Blood, The Journal of the American Society of Hematology 117 (3), 1061-1070, 2011
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
GP Linette, EA Stadtmauer, MV Maus, AP Rapoport, BL Levine, L Emery, ...
Blood, The Journal of the American Society of Hematology 122 (6), 863-871, 2013
CRISPR-engineered T cells in patients with refractory cancer
EA Stadtmauer, JA Fraietta, MM Davis, AD Cohen, KL Weber, E Lancaster, ...
Science 367 (6481), eaba7365, 2020
Engineered T cells: the promise and challenges of cancer immunotherapy
AD Fesnak, CH June, BL Levine
Nature reviews cancer 16 (9), 566-581, 2016
Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
DT Teachey, SF Lacey, PA Shaw, JJ Melenhorst, SL Maude, N Frey, ...
Cancer discovery 6 (6), 664-679, 2016
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
AP Rapoport, EA Stadtmauer, GK Binder-Scholl, O Goloubeva, DT Vogl, ...
Nature medicine 21 (8), 914-921, 2015
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies
GL Beatty, AR Haas, MV Maus, DA Torigian, MC Soulen, G Plesa, ...
Cancer immunology research 2 (2), 112-120, 2014
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells
J Scholler, TL Brady, G Binder-Scholl, WT Hwang, G Plesa, KM Hege, ...
Science translational medicine 4 (132), 132ra53-132ra53, 2012
Global manufacturing of CAR T cell therapy
BL Levine, J Miskin, K Wonnacott, C Keir
Molecular therapy Methods & clinical development 4, 92-101, 2017
Identification of a titin-derived HLA-A1–presented peptide as a cross-reactive target for engineered MAGE A3–directed T cells
BJ Cameron, AB Gerry, J Dukes, JV Harper, V Kannan, FC Bianchi, ...
Science translational medicine 5 (197), 197ra103-197ra103, 2013
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20